Home > Healthcare > Drug Device Combination > Therapeutic Systems > anal fistula treatment market
Get a free sample of Anal Fistula Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Anal Fistula Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Anal Fistula Treatment Market size was valued at around USD 728.5 million in 2023 and is estimated to grow at a CAGR of 4.4% between 2024 to 2032. This robust market growth can be attributed to factors such as the increasing prevalence of inflammatory bowel diseases, the rising incidence of anal fistulas, and the growing aging population.
The rising prevalence of inflammatory bowel diseases, including conditions such as Crohn's disease and ulcerative colitis, has led to an increased number of anal fistula cases around the world. For instance, according to a study published by Crohn’s and Colitis UK, in 2022, it was found that over half a million people in the country in UK have either Crohn's disease or ulcerative colitis. The chronic inflammation and complications associated with inflammatory bowel diseases, particularly in the perianal region, elevate the likelihood of anal fistula formation. This increased risk contributes to the growing demand for anal fistula management and treatment.
Moreover, the growing aging population contributes significantly to the rise in anal fistula cases. As individuals age, they may be more prone to certain health conditions, including inflammatory bowel diseases and infections, which are known risk factors for the development of anal fistulas. This demographic trend amplifies the overall incidence of anal fistulas, driving demand for related medical interventions.
Anal fistula treatment refers to the medical interventions and therapeutic strategies employed to address a pathological condition characterized by an abnormal tract or passage connecting the anal canal or rectum to the skin surface around the anus. The treatment aims to manage symptoms, promote healing, and prevent recurrence by addressing the underlying causes.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Anal Fistula Treatment Market Size in 2023: | USD 728.5 Million |
Forecast Period: | 2024 – 2032 |
Forecast Period 2023 - 2032 CAGR: | 4.4 |
2023 Value Projection: | USD 1.1 Billion |
Historical Data for: | 2018 – 2023 |
No of Pages: | 180 |
Tables, Charts & Figures: | 307 |
Segments Covered: | Treatment Type, Application, End-use, and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
The market is undergoing a transformative phase propelled by the escalating expenditure on research and development (R&D) and adoption of new technologies to develop novel treatments.
Based on treatment type, the market is categorized into surgical, non-surgical/fibrin glue, and medication. The surgical segment accounted for the majority share and was valued at over USD 328 million in revenue in 2023.
Based on application, the anal fistula treatment market is segmented into intersphincteric fistula, transsphincteric fistula, suprasphincteric fistula, extraphincteric fistula, and other applications. The intersphincteric fistula segment is anticipated to reach USD 288.2 million by 2032.
Based on end-use, the anal fistula treatment market is segmented into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment accounted for USD 398.6 million in revenue in 2023.
North America anal fistula treatment market accounted for USD 295 million in revenue in 2023 and is predicted to witness substantial market growth. The region's prominence is marked by a convergence of factors, including robust healthcare infrastructure, extensive research & development initiatives, and a high prevalence of inflammatory bowel diseases.
The anal fistula treatment industry is fragmented in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel treatments with improved efficiency and cost-effectiveness are among a key market strategy for anal fistula treatment products manufacturers. Some of the leading industry players including Becton, Dickinson and Company, Boston Scientific Corporation, Cook Medical, and Integra LifeSciences Holdings Corporation, among others have a substantial presence in the market.
Some of the eminent market participants operating in the anal fistula treatment industry include:
Market, By Treatment Type
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries:
Anal fistula treatment industry reached USD 728.5 million in revenue in 2023 and is set to expand at 4.4% CAGR over 2024-2032 attributed to the increasing prevalence of inflammatory bowel diseases, and the growing aging population.
The surgical segment generated more than USD 328 million in 2023 and is estimated to record substantial growth through 2032 owing to the increasing adoption of surgical treatments in minimizing symptomatic discomfort associated with anal fistulas.
North America anal fistula treatment industry accounted for USD 295 million in revenue in 2023 and is set to exhibit robust growth through 2032 driven by the robust healthcare infrastructure, extensive R&D initiatives, and a high prevalence of inflammatory bowel diseases across the region.
Some of the leading firms engaged in the anal fistula treatment industry are AbbVie, Becton, Dickinson, and Company, Biolitec AG, Boston Scientific Corporation, Coloplast Group, Cook Medical, Gem srl, KARL STORZ SE & Co. KG, Medtronic plc, Teleflex Incorporated, and Zydus Lifesciences Limited.